BioLineRx Ltd.

Healthcare · Biotechnology · Israel

Last price 1.99 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 10.41M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applic...